logo

DFTX

Definium·NASDAQ
--
--(--)
--
--(--)

DFTX fundamentals

Definium (DFTX) released its earnings on Feb 26, 2026: revenue was 0 (YoY --), met estimates; EPS was -0.51 (YoY -24.39%), missed estimates.
Revenue / YoY
0
--
EPS / YoY
-0.51
-24.39%
Report date
Feb 26, 2026
DFTX Earnings Call Summary for Q4,2025
  • Pivotal Year Ahead: 3 Phase 3 readouts in 2026 (MDD: Q2, GAD: Q3) with DT120 showing 99%+ statistical power in GAD interim analysis.
  • Strong Financial Backing: $411.6M cash runway into 2028 with focus on NDA preparation and commercial infrastructure.
  • Best-in-Class Potential: DT120 demonstrates 7.7/6.4-point HAM-A/MADRS improvements vs <4-point for current therapies.
  • Commercial Readiness: High-touch provider model with centralized hub services to streamline access and reimbursement.

Earnings

EPS
Revenue

Revenue & Expenses

Key Indicators

Definium (DFTX) key financial stats and ratios, covering profitability, financial health, and leverage.

Income Statement

Definium (DFTX)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.
Trend
Breakdown

Balance Sheet

Definium (DFTX)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.
Trend
Breakdown

Cash Flow

Definium (DFTX)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.
Trend
Breakdown

Revenue Breakdown

Where does Definium (DFTX) generate its revenue? Explore its key revenue streams and top earning regions.
By Business
Data source:
By Region
Data source:

Dividend

Track Definium (DFTX) Dividend Yield, Payout Ratio & Sustainability Through Its Dividend History
Payout Ratio
Dividend Yield